Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma 4Multiple Myeloma 3Solid Tumors 2Neoplasms 2Hematologic Neoplasms 2Sarcoma 1Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia 1Carcinoma, Hepatocellular 1Carcinoma 1Bone Marrow Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 60Cyclophosphamide 60Busulfan 43Cyclosporine 41Mycophenolic Acid 40Peripheral Blood Stem Cell Transplantation 39Cytarabine 36Whole-Body Irradiation 34Antilymphocyte Serum 29Filgrastim 26Tacrolimus 24Methotrexate 24fludarabine 23Cord Blood Stem Cell Transplantation 22Radiotherapy 21Melphalan 20Etoposide 18Methylprednisolone 15Azacitidine 14Granulocyte Colony-Stimulating Factor 13Idarubicin 12Daunorubicin 11Thiotepa 10sargramostim 8Cyclosporins 8Clofarabine 7Arsenic Trioxide 7Transplantation 6Topotecan 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × darinaparsin × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡